Rubén Alexander Elzaurdín Mora¹* and Noralys Lara Fernández²

¹Specialist I Degree in Medical Oncology, Diploma in Oncological Radiotherapy, Medical-Surgical Research Center, Havana, Cuba
²Specialist I Degree in Medical Oncology, Miguel Enríquez General Teaching Hospital, Havana, Cuba

*Corresponding Author: Rubén Alexander Elzaurdín Mora, Specialist I Degree in Medical Oncology, Diploma in Oncological Radiotherapy, Medical-Surgical Research Center, Havana, Cuba.

Received: April 20, 2022; Published: June 18, 2022

Abstract

The evolution to novel teams of treatment with radiations and the design of new techniques for the planning of the therapy of the patients with lung cancer has allowed to find the balance between the toxicities of the organs of risk and the therapeutic dose. The presence of these organs reveille, it can impede the capacity to administer a complete program of radiotherapy. The coming of new teams for the acquisition of more precise images and the development of such advanced techniques as the radiotherapy of modulated intensity (IMRT), Volumetric Modulated Arc Therapy (VMAT) and the Stereotactic Body Radiation (SBRT), they achieve the increment of radiation dose to the tumoral region, it improves the tolerance of the treatment fields, it reduces the dose of radiations to receive for the organs of risk, guaranteeing this way a better objective answer. The objective of the present revision is to promote the knowledge of the new radiotherapy techniques and to foment this way its application in the treatment of the cancer of lung of non-small cells with the purpose of improving the grade of objective answer and the survival of the patients.

Keywords: Lung Cancer; Radiotherapy; Radiotherapy of Modulated Intensity; Organs of Risk

References

1. Arrieta O., et al. “Lung Cancer Consensus". Revista de Investigación Clínica 65 (2013): s5-s84.
2. Jemal A., et al. “Global cancer statistics”. CA: A Cancer Journal for Clinicians 2 (2011): 69-90.
3. Santini Blasco A. “Advances in radiation therapy in the treatment of lung cancer”. Trends in Medicine November; Year XXVI.51 (2017): 67-76
4. cancer.org Copyright © 2014 The American Cancer Society, Inc.
5. Siegel R., et al. “Cancer statistics 2017”. CA: A Cancer Journal for Clinicians 67 (2017): 7-30.
6. Sause W. “The role of Radiotherapy in Non-Small cell Lung Cancer”. Chest 116 (1999): 6-504s-508s.
7. Diwanji T., et al. “Advances in Radiotherapy techniques an delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy”. Translational Lung Cancer Research 2 (2017): 131-147.
8. Senan S. “Treatment of stage IIIA non-small cell lung cancer: Charting the next step”. Journal of Oncology Practice (2016): 12609-12610.
9. Baker S., et al. “A Critical review of recent developments in radiotherapy for non-small cell lung cancer”. Radiation Oncology 11 (2016): 115-121.
10. Mir EYL., et al. “Oncospecific treatment in elderly patients with lung, breast and lymphoma cancer”. Geroinfo3 (2019).
11. Noone A., et al. SEER Cancer Statistics Review, 1975 2015, based on November 2017 SEER data submission, posted to the SEER web site, april 2018. Bethesda, MD: National cancer Institute (2018).
12. Ferlay J., et al. “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. International Journal of Cancer5 (2014): E359-386.
13. Freddie Bray. “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”. CA: A Cancer Journal for Clinicians 68 (2018): 394-424.
14. Siegel RL., et al. “Cancer statistics, 2015”. CA: A Cancer Journal for Clinicians 1 (2015): 529.
15. Howlader N., et al. “SEER Cancer Statistics Review, 1975-2012”. Natl. Cancer Institute, Bethesda, MD (2015).
16. Ferlay J., et al. “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. International Journal of Cancer5 (2014): E359-386.
17. “Statistical yearbook of health”. ISSN electron version (2013): 1561-4433.
18. Travis WD., et al. “The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification”. Journal of Thoracic Oncology 9 (2015): 1243-1260.
19. García de Vinuesa Calvo G. “Anatomopathological classification”. Spanish Journal of Thoracic Pathology2 (2017): 13-24.
20. Detterbeck FC., et al. “The stage classification of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines”. Chest 143 (2013): e191S-210S.
21. Mountain CF. “A new international staging system for lung cancer”. Chest 89 (1986): 225S-233S.
22. Rodríguez Serre J E., et al. “Clinical, tomographic and histopathological characterization of patients with lung cancer”. MEDISAN9 (2018): 1138.
23. Brunelli A., et al. “ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)”. European Respiratory Journal 1 (2019): 17-41.
24. Soto N., et al. “Stereotactic body radiotherapy in lung neoplasms”. Health technology assessment documents, rapid response report. No 660, Buenos Aires, Argentina, July (2018): 1668-2793.
25. Timmerman R., et al. “Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer”. JAMA 11 (2010).
26. Grutters JPC., et al. “Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis”. Radiotherapy Oncology1 (2010): 32-40.
27. Manterola A and Colab. “Clinical application of intensity-modulated radiotherapy”. Anales del sistema sanitario de Navarra 32 (2009): 21-31.

Citation

Citation: Rubén Alexander Elzaurdín Mora and Noralys Lara Fernández. “New Radiation Therapy Techniques in Non-small Cell Lung Cancer". Acta Scientific Otolaryngology 4.7 (2022): 27-31.

Copyright

Copyright: © 2022 Rubén Alexander Elzaurdín Mora and Noralys Lara Fernández. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.